A new prognostic tool, termed IPS-E, designed by researchers from the Institute of Oncology Research (Bellinzona, Switzerland), predicts how long a patient diagnosed with chronic lymphocytic leukemia (CLL) will be able to wait before starting treatment for their cancer. Recently published in Blood, it is hoped the tool will become a point-of-care resource to improve clinical decision making.
“While some patients display a milder disease never requiring therapy, others present active disease shortly after diagnosis and require intervention,” commented Davide Rossi (Institute of Oncology Research). “The IPS-E is a simple and a robust prognostic tool based on routine clinical and laboratory variables. The simplicity of IPS-E should facilitate its translation to the clinic.”
To view the full article, please register now for access